Antimicrobial Resistance in Gram-Negative Hospital Isolates: Results of the Turkish HITIT-2 Surveillance Study of 2007

作者:Gur D*; Hascelik G; Aydin N; Telli M; Gultekin M; Ogunc D; Arikan O A; Uysal S; Yaman A; Kibar F; Gulay Z; Sumerkan B; Esel D; Kayacan C B; Aktas Z; Soyletir G; Altinkanat G; Durupinar B; Darka O; Akgun Y; Yayla B; Gedikoglu S; Sinirtas M; Berktas M; Yaman G
来源:Journal of Chemotherapy, 2009, 21(4): 383-389.
DOI:10.1179/joc.2009.21.4.383

摘要

Resistance rates to amikacin, ciprofloxacin, ceftazidime, cefepime, imipenem, cefoperazone/sulbactam and piperacillin/tazobactam in Escherichia coli (n = 438), Klebsiella pneumoniae (n = 444), Pseudomonas aeruginosa (n = 210) and Acinetobacter baumanni (n =200) were determined with E-test in a multicenter surveillance study (HITIT-2) in 2007. ESBL production in Escherichia coli and K. pneumoniae was investigated following the CLSI guidelines. Overall 42.0% of E.coli and 41.4% of K. pneumoniae were ESBL producers. In E. coli, resistance to imipenem was not observed, resistance to ciprofloxacin and amikacin was 58.0% and 5.5% respectively. In K. pneumoniae resistance to imipenem, ciprofloxacin and amikacin was 3.1%, 17.8% 12.4% respectively. In P. aeruginosa the lowest rate of resistance was observed with piperacillin/tazobactam (18.1%). A. baumanni isolates were highly resistant to all the antimicrobial agents, the lowest level of resistance was observed against cefoperazone/sulbactam (52.0%) followed by imipenem (55.5%). This study showed that resistance rates to antimicrobials are high in nosocomial isolates and show variations among the centers.

  • 出版日期2009-8